





## Research Paper

## A dual functional theranostic microneedle patch for immunomodulation and real time monitoring in diabetic wound therapy

Shuai Fan<sup>1,2,3,#</sup>, Junlong Zhong<sup>1,2,#</sup>, Yeke Chen<sup>3,5,#</sup>, Kang Chen<sup>4</sup>, Zhiming Liu<sup>1,2</sup>, Xinmin Yang<sup>4</sup>, Wen Tan<sup>4</sup>, Wenlong Tang<sup>3,4</sup>, Wanhui Zhou<sup>3,4</sup>, Degui Wu<sup>3,4</sup>, Jiachao Xiong<sup>1,2</sup>, Zhenhai Zhou<sup>1,2</sup>, Fanrong Ai<sup>3</sup>, Kai Cao<sup>2,3,4</sup>

1. Orthopedic Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330209, China.
2. The Key Laboratory of Spine and Spinal Cord Disease of Jiangxi Province, Nanchang, Jiangxi 330006, China.
3. Bio 3D Printing Laboratory, School of Advanced Manufacturing, Nanchang University, Nanchang, Jiangxi 330031, China.
4. Department of Orthopedics, Affiliated Rehabilitation Hospital of Nanchang University, Jiangxi 330003, China.
5. The Second Clinical Medical School, Nanchang University, Nanchang, Jiangxi 33006, China.

#Shuai Fan, Junlong Zhong and Yeke Chen contributed equally to this work.

 Corresponding authors: Zhenhai Zhou (Email: zhouzhenhai2016@126.com); Fanrong Ai (Email: afr3755875@126.com); Kai Cao (Email: caokai@ncu.edu.cn, kaichaw@126.com).

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>). See <https://ivyspring.com/terms> for full terms and conditions.

Received: 2026.02.24; Accepted: 2026.04.10; Published: 2026.05.01

### Abstract

**Rationale:** The management of diabetic wound is limited by the absence of delivery systems that can dynamically respond to the complex pathological microenvironment. Herein, we have engineered a dual-functional theranostic microneedle (MN) patch for intelligent diabetic wound therapy.

**Methods:** The patch (termed MNs@Z/CP) features a spatially designed bilayer architecture: the needle tips are loaded with a catalytic nanozyme (ZTCG) for on-demand therapy, exhibiting cascade superoxide dismutase (SOD)- and catalase (CAT)-mimetic activities to simultaneously alleviate oxidative stress and hypoxia while combating bacterial infection; the backing layer incorporates a cerium metal-organic framework (Ce-MOF)-based visual sensor for real-time monitoring of wound H<sub>2</sub>O<sub>2</sub> levels.

**Results:** MNs@Z/CP not only exhibited multimodal antibacterial and anti-inflammatory effects but also reprogrammed the immune microenvironment by activating the Nrf2/HO-1 pathway to shift macrophages from a pro-inflammatory (M1) to a pro-healing (M2) phenotype. In both diabetic and methicillin-resistant *Staphylococcus aureus* (MRSA)-infected diabetic wound models, the patch significantly accelerated wound closure, promoting angiogenesis, collagen deposition, and re-epithelialization.

**Conclusion:** This work pioneers a theranostic platform that integrates real-time diagnostic, controlled catalytic therapy, and immunomodulatory therapy, providing a viable approach to the autonomous management of chronic wounds.

Keywords: diabetic wound healing, microneedle patches, metal-organic frameworks, macrophage reprogramming

### Introduction

Diabetes is a global health challenge characterized by persistent hyperglycemia resulting from insulin deficiency or dysfunctional insulin action [1]. Diabetic ulcers are among the most common and therapeutically challenging complications of diabetes, affecting approximately 19–34% of diabetic patients [2]. These ulcers are linked to high recurrence rates and significant disability, imposing a tremendous strain on both patients and healthcare systems [3].

Unlike normal wound healing, diabetic ulcers remain arrested in a persistent inflammation-infection phase, failing to progress through the normal tissue repair program [4].

The hyperglycemic microenvironment is a pivotal driver of poor diabetic wound healing [5]. Persistent hyperglycemia induces oxidative stress, leading to the massive accumulation of reactive oxygen species (ROS), including hydrogen peroxide

(H<sub>2</sub>O<sub>2</sub>), hydroxyl radicals ( $\cdot$ OH), and superoxide anions ( $\cdot$ O<sub>2</sub><sup>-</sup>), thereby inducing cellular damage and DNA strand breaks [6, 7]. Concurrently, the hyperglycemic microenvironment alters the local immune status, promoting the adhesion, colonization, and biofilm formation of pathogenic microorganisms [8]. These extracellular polymeric substances-based biofilm structures further enhance bacterial resistance to antibiotics, while the persistent release of metabolic toxins from bacteria exacerbates tissue damage, thereby forming a vicious cycle of "infection-inflammation-tissue damage" [9]. In addition, diabetic wounds exhibit dysfunction of the endogenous antioxidant defense system, such as the Nrf2 signaling pathway [10]. This weakens the body's ability to clear excess ROS, thereby affecting key repair processes like cell proliferation, macrophage polarization, and angiogenesis [11]. Notably, there is a significant synergistic amplification effect between inflammation and oxidative stress: inflammatory responses promote H<sub>2</sub>O<sub>2</sub> generation, and H<sub>2</sub>O<sub>2</sub> accumulation further activates inflammatory pathways, establishing a positive feedback loop [12]. Consequently, developing comprehensive treatment strategies capable of simultaneously mitigating oxidative stress and dynamically monitoring inflammation is crucial for diabetic wound management.

Metal-Organic Frameworks (MOFs) have been widely used in wound healing applications due to their high specific surface area, tunable porosity, and excellent biocompatibility [13-15]. However, conventional MOFs often exhibit limited functionality and insufficient intrinsic antibacterial activity. Therefore, they fail to meet the complex demands of diabetic wound therapy, which requires efficient antibacterial effects, antioxidant stress capacity, and pro-angiogenic activity [16, 17]. Passive dressings commonly used in clinical practice do not provide real-time feedback on wound status, making the treatment process a "black box" and impeding precise intervention [18]. Although various H<sub>2</sub>O<sub>2</sub> monitoring technologies based on quantum dots, MOF-based sensors, and upconversion nanoparticles have recently emerged, most of these systems lack the capability to integrate monitoring functions with therapeutic functions [19, 20]. Advances in smart wound microneedle patches offer a promising approach to overcome these restrictions [21, 22]. By constructing a dual-functional system that combines monitoring and treatment, it becomes possible to intervene in the wound microenvironment and significantly enhance healing efficiency. Among the numerous measurable biochemical indicators, H<sub>2</sub>O<sub>2</sub> serves as a key molecule that reflects oxidative stress

and inflammation levels, providing essential dynamic information for assessing wound status and therapeutic efficacy [23, 24].

In this study, we designed a dual-MOF-based bilayer multifunctional microneedle (MN) patch (MNs@Z/CP) (Scheme 1). This system integrated multi-enzyme catalysis, efficient antibacterial activity, macrophage reprogramming, and real-time H<sub>2</sub>O<sub>2</sub> monitoring to achieve synergistic therapy and management of diabetic wounds. The needle layer was composed of hyaluronic acid methacryloyl (HAMA) hydrogel loaded with ZTCG nanozyme, exhibiting cascade catalase (CAT)- and superoxide dismutase (SOD)-mimetic catalytic activities and potent antibacterial capability. The backing layer consisted of polycaprolactone (PCL) electrospun fibers coated with Ce-MOF (CP), enabling visual monitoring of wound status through its colorimetric response to H<sub>2</sub>O<sub>2</sub> [25]. By triggering the endogenous Nrf2/HO-1 signaling pathway, MNs@Z/CP polarizes macrophages toward the M2 phenotype *in vitro*. This reduced oxidative damage and encouraged cell migration and proliferation. *In vivo* experiments further confirmed that MNs@Z/CP effectively promoted angiogenesis, collagen deposition, and re-epithelialization, while simultaneously suppressing excessive inflammation and inducing M2 macrophage polarization to remodel the healing microenvironment. Transcriptomic analysis revealed that MNs@Z/CP significantly accelerated diabetic wound healing through the synergistic "anti-inflammatory and pro-proliferative" effects. Moreover, the system demonstrated excellent therapeutic outcomes in a methicillin-resistant *Staphylococcus aureus* (MRSA)-infected diabetic wound model. This study provided a novel and comprehensive intelligent solution for chronic wounds by integrating regulation of the microenvironment with multi-enzyme catalytic therapy and real-time monitoring capability.

## Materials and Methods

### Materials


Zinc nitrate hexahydrate (Zn(NO<sub>3</sub>)<sub>2</sub>·6H<sub>2</sub>O), 2-methylimidazole (2-MIM), tannic acid (TA), ceric ammonium nitrate ((NH<sub>4</sub>)<sub>2</sub>Ce(NO<sub>3</sub>)<sub>6</sub>), riboflavin, methionine, chloroform, and terephthalic acid (TPA) were purchased from Aladdin. Nitrotetrazolium blue chloride (NBT), copper chloride dihydrate (CuCl<sub>2</sub>·2H<sub>2</sub>O), gallium nitrate, dimethylformamide (DMF) and ferrous sulfate (FeSO<sub>4</sub>) were purchased from Macklin. Poly( $\epsilon$ -caprolactone) (PCL) was sourced from Sigma-Aldrich. Hyaluronic acid methacryloyl (HAMA) was purchased from EFL. The

specialized medium for HUVECs was procured from Sciencell.

## Characterization

The morphological features were characterized by transmission electron microscope (TEM, FEI Talos F200S) and scanning electron microscope (SEM, Apreo 2S Hivac, Thermo Scientific). Crystal structures were investigated by X-ray diffraction (XRD, D8 Advance, Bruker) and X-ray photoelectron spectroscopy (XPS, ESCALAB250Xi, Thermo

Scientific). Fourier transform infrared (FTIR) spectra were recorded using an FTIR spectrometer (Nicolet iS20, USA). The hydrodynamic size and zeta potential were determined by zetasizer nano ZS90 (Malvern Instruments). Mechanical testing was conducted on a universal testing machine (CMT6104). Electron spin resonance (ESR/EPR) spectra were acquired using a Bruker EMXplus-6/1 spectrometer. Flow cytometry data were collected using a FACS Calibur cell analyzer.



**Scheme 1.** The schematic illustrates the fabrication process of the MNs@Z/CP patch and its mechanism for accelerating diabetic wound healing, which involves H<sub>2</sub>O<sub>2</sub> visual monitoring, ROS scavenging, biofilm disruption, and macrophage reprogramming.

## Synthesis of ZTCG

Briefly, aqueous solutions of 2-MIM (2.2 g in 10 mL water) and  $\text{Zn}(\text{NO}_3)_2 \cdot 6\text{H}_2\text{O}$  (2 mL, 100 mg/mL) were combined and stirred for 15 min. ZIF-8 was recovered via centrifugation [26]. After ZIF-8 was dispersed in deionized water (10 mg/mL), 10 mL of TA solution (10 mg/mL) was added, and the mixture was stirred for 10 min. The resulting ZT nanoparticles were collected and redispersed in 10 mL of deionized water. Subsequently, the ZT dispersion was combined with 400  $\mu\text{L}$  of  $\text{CuCl}_2 \cdot 2\text{H}_2\text{O}$  (10 mg/mL) and 2 mL of gallium nitrate (10 mg/mL) under stirring. Centrifugation was used to separate the final ZTCG product following a 10-min reaction.

## Synthesis of Ce-MOF and OXCe-MOF

TPA (0.146 g) was dissolved in 2.5 mL of DMF, and 250  $\mu\text{L}$  of triethylamine was added to enhance solubility [27]. Separately,  $(\text{NH}_4)_2\text{Ce}(\text{NO}_3)_6$  (1.000 g) was dissolved in 4 mL of DMF. The TPA solution was then combined with the cerium salt solution under stirring. After 24 h of reaction, Ce-MOF was collected by centrifugation. The Ce-MOF oxidized by hydrogen peroxide is denoted as OXCe-MOF.

## Fabrication of bilayer microneedles (MNs)

First, Ce-MOF-loaded electrospun fibers were prepared. Briefly, PCL (18 wt%) was dissolved in 10 mL of chloroform. The spinning solution was then loaded into a syringe. The PCL electrospun fiber membrane was fabricated at room temperature using the following parameters: an applied voltage of 10 kV, a solution flow rate of 0.8 mL/h, and a collection distance of 13 cm. An ethanol solution of Ce-MOF (2 mg/mL) was sprayed onto the PCL membrane surface three times. After drying for 24 h, the Ce-MOF/PCL (CP) electrospun membrane was obtained.

The ZTCG-HAMA precursor solution was prepared by dispersing ZTCG (200  $\mu\text{g}/\text{mL}$ ) into a HAMA solution (5% w/v) followed by the addition of a 0.25% w/v lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) solution. Then, 300  $\mu\text{L}$  of the ZTCG-HAMA precursor solution was cast into a polydimethylsiloxane (PDMS) mold. After centrifugation and vacuum degassing, the ZTCG-HAMA (MNs@Z) was dried at 30 °C for 6 h. Subsequently, the CP fibrous mat was attached as the backing layer. The MNs@Z/CP was then polymerized and demolded. Blank HAMA hydrogel microneedles (MNs) with PCL film (P) were denoted as MNs/P, while ZTCG-loaded HAMA hydrogel microneedles (MNs@Z) with PCL film (P) were denoted as MNs@Z/P.

## ROS-responsive drug release

ZTCG samples (200  $\mu\text{g}/\text{mL}$ ) were incubated in 5 mL of phosphate-buffered saline (PBS) with or without  $\text{H}_2\text{O}_2$  (300  $\mu\text{M}$ ). At predefined intervals (3, 6, 12, and 24 h), samples were collected for examination. The release of  $\text{Cu}^{2+}$  and  $\text{Ga}^{3+}$  was quantified using inductively coupled plasma optical emission spectrometry (ICP-OES).

## $\cdot\text{O}_2^-$ scavenging assay

The inhibition rate of NBT photoreduction was used to assess the ZTCG nanozymes' capacity to scavenge  $\cdot\text{O}_2^-$ . ZTCG nanozymes (0–200  $\mu\text{g}/\text{mL}$ ) were mixed with 20  $\mu\text{M}$  riboflavin, 12.5 mM methionine, and 75  $\mu\text{M}$  NBT. Following 15 min of UV irradiation,  $\cdot\text{O}_2^-$  reduced NBT to blue formazan. The absorbance was measured by Ultraviolet-Visible (UV-Vis, Lambda 1050+, PerkinElmer) at 560 nm.

## $\cdot\text{OH}$ scavenging assay

The  $\cdot\text{OH}$  scavenging effectiveness was ascertained using a salicylic acid (SA) trapping method. Briefly,  $\cdot\text{OH}$  radicals were generated via the Fenton reaction between  $\text{H}_2\text{O}_2$  ( $2 \times 10^{-4}$  M) and  $\text{FeSO}_4$  ( $2 \times 10^{-4}$  M). ZTCG nanozymes (0–200  $\mu\text{g}/\text{mL}$ ) were added to scavenge the  $\cdot\text{OH}$ . Subsequently, SA ( $1 \times 10^{-3}$  M) was added to react with the residual  $\cdot\text{OH}$ , forming purple-colored 2,3-dihydroxybenzoic acid. The absorbance was measured at 510 nm.

## ABTS $\cdot$ and DPPH $\cdot$ scavenging assays

In short, the ABTS $\cdot$  cation was generated by mixing potassium persulfate (2.6 mM, 1 mL) with ABTS (7.4 mM, 1 mL) and leaving the mixture in the dark for 16 h. PBS was used to dilute the resultant ABTS $\cdot$  solution 30-fold. ZTCG nanozymes (0–200  $\mu\text{g}/\text{mL}$ ) were dispersed in the ABTS $\cdot$  solution, and the combination was then kept in the dark for 20 min. Absorbance was measured at 734 nm. The ABTS $\cdot$  scavenging rate was calculated using the formula: Scavenging (%) =  $(A_0 - A) / A_0 \times 100\%$ , where  $A_0$  and A are the absorbance values without and with ZTCG.

To test the DPPH $\cdot$  scavenging activity, ZTCG nanozymes (0–200  $\mu\text{g}/\text{mL}$ ) were reacted with DPPH $\cdot$  solution in dark for 5 min. At 517 nm, the absorbance was measured. The DPPH $\cdot$  scavenging rate was calculated using the formula: Scavenging (%) =  $(A_0 - A) / A_0 \times 100\%$ , where  $A_0$  and A are the absorbance values without and with ZTCG.

## CAT-like activity of ZTCG nanozymes

The ZTCG nanozyme (0–200  $\mu\text{g}/\text{mL}$ ) was mixed with  $\text{H}_2\text{O}_2$  in PBS (0.1 M) to evaluate its CAT-like activity. The oxygen ( $\text{O}_2$ ) generated was quantified using a dissolved oxygen meter. Additionally, the

H<sub>2</sub>O<sub>2</sub> scavenging activity of ZTCG was measured by commercial hydrogen peroxide assay kit (Solarbio).

### Electrochemical measurements of ZTCG nanozymes

Cyclic voltammetry (CV) was measured in PBS with or without H<sub>2</sub>O<sub>2</sub> (300 µg/mL) at a scan rate of 50 mV/s by an electrochemical workstation (CHI 760E, China). A standard three-electrode system was employed, with a glassy carbon electrode modified by ZTCG serving as the working electrode, a platinum wire serving as the counter electrode, and an Ag/AgCl electrode as the reference electrode.

### Antibacterial activity of ZTCG nanozymes

*MRSA* (ATCC33591) and *Escherichia coli* (*E. coli*, ATCC25922) were selected as model strains. ZTCG nanozymes (0-200 µg/mL) were co-cultured with bacterial suspension (2 mL, 10<sup>8</sup> CFU/mL) for 6 h. After co-culture, the suspensions were diluted 10<sup>4</sup>-fold and plated on agar plates for measurement. For bacterial morphology observation, the co-cultured bacterial suspensions were fixed, dehydrated, freeze-dried, and observed by SEM and TEM.

### Biofilm eradication assay of ZTCG nanozymes

To create *E. coli* and *MRSA* biofilms, cell culture slides and bacterial (10<sup>8</sup> CFU/mL, 2 mL) were added in 12-well plates for three days. Following 24 h treatment with various concentrations of ZTCG solution, the pre-formed biofilms were rinsed twice with PBS. The biofilms were stained with 0.1% crystal violet solution and examined by optical microscope. The absorbance (OD) at 595 nm was determined after the stained biofilms were solubilized in ethanol. Elimination rate (%) = (OD<sub>0</sub> - OD<sub>Z</sub>) / OD<sub>0</sub> × 100%, where OD<sub>0</sub> and OD<sub>Z</sub> represent the OD values without and with ZTCG treatment, respectively. Additionally, the biofilms were stained with Bacterial Live/Dead Staining Kit (Beyotime) and imaged with a laser scanning confocal microscope (CLSM, OLYMPUS FV1000).

### Bacterial membrane permeability of ZTCG nanozymes

The membrane permeability of *MRSA* biofilms was measured using the o-nitrophenyl-β-D-galactopyranoside (ONPG) hydrolysis experiment. In summary, *MRSA* biofilms were exposed to various concentrations of ZTCG nanozymes for 24 h. Following centrifugation, the supernatant was examined by an ONPG test kit (Solarbio, Beijing, China). The absorbance of the supernatant was measured at 420 nm.

### Protein leakage

After co-incubating different concentrations of the ZTCG nanozyme with the *MRSA* suspension for 48 h, the mixture was centrifuged at 5000 rpm (4 °C, 10 min) to obtain the supernatant. Protein leakage was quantified using a BCA protein assay kit (Beyotime).

### Bacterial membrane potential detection

The DiSC<sub>3</sub>(5) fluorescent probe was used to measure bacterial membrane potential. After co-culturing of *MRSA* suspensions (10<sup>6</sup> CFU/mL) with various concentrations of ZTCG nanozymes, the fluorescence signal was visualized under a CLSM.

### Cytocompatibility assay

In 24-well plates, L929 fibroblasts and HUVECs (2 × 10<sup>4</sup>) were seeded and treated with various MNs. Cell viability was assessed using CCK-8 reagent (Solarbio, China), and cell morphology was observed by Calcein-AM/PI staining (dark, 20 min) on days 1 and 3.

### Intracellular ROS scavenging

The intracellular ROS scavenging capacity of MNs@Z/CP was evaluated using a hydrogen peroxide-induced oxidative stress model. After seeding in 24-well plates, L929 cells were cultivated for 24 h, then exposed to MNs/P, MNs@Z/P, and MNs@Z/CP in 300 µM H<sub>2</sub>O<sub>2</sub> for 24 h. After stained with DCFH-DA (5 µM), the cells cleaned with PBS and observed under a fluorescence microscopy. Cell viability under oxidative stress was separately performed using Calcein-AM/PI staining and CCK-8 assay.

### Cell proliferation assays

In the EdU assay, L929 cells were treated with MNs/P, MNs@Z/P, and MNs@Z/CP along with H<sub>2</sub>O<sub>2</sub> (300 µM) for 24 h, followed by the addition of EdU (10 µM) and further incubation for 12 h. Following the kit's instructions for fixation, permeabilization, blocking, and staining, fluorescence microscopy was used to obtain fluorescence pictures.

### Wound scratch assay

After seeding L929 cells (2 × 10<sup>5</sup>) in 24-well plates, a linear scratch wound was created using a sterile 200 µL pipette tip. The experimental groups were treated with MNs/P, MNs@Z/P, and MNs@Z/CP along with H<sub>2</sub>O<sub>2</sub> (300 µM). Microscopy was used to take pictures of the scratch wounds, and quantitative analysis was performed with ImageJ.

### Tube formation assay

Matrigel (50 µL) was added to 96-well plates and

polymerized at 37 °C (30 min). HUVECs ( $1 \times 10^4$ ) were seeded onto the Matrigel and exposed to MNs/P, MNs@Z/P, and MNs@Z/CP along with H<sub>2</sub>O<sub>2</sub> (300  $\mu$ M) for 6 h. Images were acquired using a microscope and quantitatively analyzed with ImageJ.

### Intracellular ROS scavenging by MNs@Z/CP in cells

In 24-well plates, RAW 264.7 macrophages ( $2 \times 10^4$ ) were seeded and stimulated with LPS (100 ng/mL, 12 h). After that, the cells were co-cultured with MNs/P, MNs@Z/P, and MNs@Z/CP for 24 h. The cells staining was performed using 5  $\mu$ M DCFH-DA, followed by PBS washes and fluorescence microscopic imaging.

### Mitochondrial membrane potential ( $\Delta\Psi_m$ ) assay

After treatment with LPS and the materials, cells were stained for 30 min (37 °C, dark) using 5  $\mu$ M JC-1 solution. After washing with PBS, the cells were observed under CLSM.

### Evaluation of macrophage polarization phenotypes

Following a 12-h stimulation with LPS (100 ng/mL), the macrophages were treated with MNs/P, MNs@Z/P, and MNs@Z/CP for 24 h. Following their fixation in 4% paraformaldehyde and processed according to a standard immunofluorescence protocol. This included blocking, incubation with iNOS and CD206 primary antibodies (4 °C, overnight), and subsequent treatment with secondary antibodies for 30 min. Nuclei were delineated using DAPI staining. Imaging was performed using a CLSM, quantitative analysis of the fluorescence signal was carried out with ImageJ.

For real-time quantitative polymerase chain reaction (RT-qPCR), TRIzol reagent was used to extract total RNA from treated macrophages. After reverse transcription into complementary DNA, the mRNA expression levels of *iNOS*, *IL-6*, *TNF- $\alpha$* , *CD206*, and *IL-10* were determined. The primer sequences are listed in Table S1. Western blot (WB) was employed to detect iNOS and CD206 protein expression and quantified using ImageJ. The primary antibodies are listed in Table S2.

### In vitro anti-inflammatory mechanism of MNs

Immunofluorescence staining was used to assess Nrf2 and HO-1 expression. Meanwhile, the expression levels of Nrf2, KEAP1, HO-1, CAT, and NOX1 were assessed by RT-qPCR and WB analysis.

### Animal models and treatments

All animal procedures were conducted in strict compliance with the national guidelines for animal welfare and ethical review and were approved by the Animal Ethics Committee of Nanchang University (Nanchang, China, Approval No. NCULAE-202209280028). Sprague-Dawley rats (male, 8-week-old) were purchased from Changsha Tianqin Biotechnology Co., Ltd. Streptozotocin (STZ, 45 mg/kg) injections were used to cause diabetes following a week of acclimation. The rats were monitored daily. The tail vein was used to assess blood glucose levels at random time points. Sustained elevated blood glucose (>16.7 mmol/L) was classified as diabetic and used for subsequent experiments.

Diabetic rats were randomly assigned to four groups (n = 15): blank group, MNs/P group, MNs@Z/P group, and MNs@Z/CP group. A full-thickness skin wound (10 mm diameter) was made on the dorsal skin. The blank group received no treatment, while the other three groups were treated with MNs/P, MNs@Z/P, or MNs@Z/CP patches, respectively. The wound healing process (0, 3, 7 and 12 days) was periodically photographed and quantitatively analyzed by ImageJ software. At the predetermined endpoints, tissue samples were harvested for histological evaluation and transcriptome sequencing.

To produce the MRSA-infected diabetic wound model, diabetic rats received full-thickness wounds (10 mm in diameter), followed by injection of 50  $\mu$ L of MRSA suspension ( $10^8$  CFU/mL) into the wound site. The MNs application regimen and experimental groups were consistent with the dorsal wound experiment. The wound healing process (0, 4, 9 and 15 days) was periodically photographed and quantitatively analyzed by ImageJ software. Microbial assessment involved serial dilution and plating of wound exudates collected on postoperative days 4 and 9 on LB agar.

### Histological staining

After fixation, wound tissue samples were embedded in paraffin and cut into approximately 5- $\mu$ m-thick slices for subsequent H&E, Masson's trichrome, Giemsa, and immunohistochemical and fluorescence staining. Quantitative analysis was performed with ImageJ software.

### In vivo biosafety assessment

On day 15, major organs were harvested from rats and stained with H&E to detect any potential abnormalities induced by the MNs@Z/CP treatment.

## Transcriptome sequencing (RNA-Seq)

Wound tissues from the blank group and MNs@Z/CP-treated group ( $n = 3$ ) of diabetic rats were harvested on postoperative day 12 for RNA sequencing (diabetic wound model). After assessing RNA purity and integrity, the qualified RNA was processed into cDNA libraries and subjected to paired-end sequencing. An Illumina NovaSeq X Plus platform was used for the sequencing process. Differential gene expression analysis, Gene Ontology (GO) enrichment analysis, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were conducted.

## Statistical analysis

At least three independent repetitions of each experiment were conducted, and the data were displayed as mean  $\pm$  SD. Statistical analyses for all comparative studies in this work was evaluated using GraphPad Prism software (9.2.0). One-way analysis of variance (ANOVA) and *t*-test were used for statistical analyses. Statistical significance is denoted as \* $p < 0.05$ , \*\* $p < 0.01$ , and \*\*\* $p < 0.001$ .

## Results and Discussion

### Preparation and characterization of ZTCG nanozymes

ZIF-8 nanoparticles were initially synthesized using a one-pot approach [28]. As shown in Figure 1A, the as-prepared ZIF-8 nanoparticles exhibited a typical polyhedral morphology. Tannic acid (TA) was then introduced onto their surface to form ZT composites. The TA layer not only provided strong chelating capacity but also etched the ZIF-8 core, transforming it into a hollow spherical structure (Figure 1A) [26]. Subsequently, copper (Cu) and gallium (Ga) ions were added to form a stable TA-CuGa metal-phenolic network (MPN). This process ultimately produced the ZTCG nanozymes with a hollow structure (Figure 1A). SEM imaging revealed that the surface of ZTCG was relatively rough, whereas the original ZIF-8 surface was smooth (Figure 1B). The energy dispersive X-ray spectroscopy (EDS) results verified the presence of Zn, Cu, Ga, C, and O in the ZTCG nanozymes (Figure 1C, Figure S1 and S2), confirming successful MPN coating. Dynamic light scattering (DLS) measurements showed that all samples had a hydrodynamic diameter of approximately 150 nm. However, a slight increase in the size of the ZTCG nanozymes was observed after MPN functionalization (Figure 1D). Zeta potential measurements provided further evidence for successful synthesis of ZTCG (Figure 1E). The original ZIF-8 nanoparticles possessed a surface

charge of  $+17.6 \pm 0.66$  mV. After TA etching, the zeta potential of ZT reversed significantly to  $-29.4 \pm 0.2$  mV. Following the addition of  $\text{Cu}^{2+}$  and  $\text{Ga}^{3+}$ , the zeta potential of ZTCG nanozymes shifted slightly to  $-25.33 \pm 0.35$  mV. These changes verified the successful coordination between TA and metal ions.

The XRD pattern in Figure 1F demonstrated that the crystal structure of ZIF-8 was not significantly altered by TA etching alone. The ZT composite retained the characteristic peaks of ZIF-8 at  $7.05^\circ$  and  $12.54^\circ$ , and an additional diffraction peak corresponding to TA appeared at  $24.72^\circ$ . However, the persistent etching effect of TA caused the ZTCG nanozymes to change into an amorphous structure after the MPN shell formed, resulting in the complete disappearance of the characteristic ZIF-8 diffraction peaks. The chemical structure was further characterized by FTIR spectroscopy (Figure 1G). In contrast to ZIF-8, ZT showed a stretching vibration peak at  $1720\text{ cm}^{-1}$ , which matched the C=O bond in ester groups. The broad peak of ZT in the  $3200\text{--}3500\text{ cm}^{-1}$  region was much more pronounced, owing to O-H vibrations from the numerous hydroxyl groups in TA [29]. Concurrently, encapsulation of the ZIF-8 core by the MPN shell significantly reduced the intensity of the Zn-N vibration peak at  $678\text{ cm}^{-1}$  [30]. The full-scale XPS survey spectrum (Figure 1H) clearly showed characteristic peaks for C 1s, N 1s, O 1s, Zn 2p, Cu 2p, and Ga 3d, confirming successful modification by the MPN network. The high-resolution Cu 2p spectrum (Figure 1I) showed a mixed valence state of  $\text{Cu}^+/\text{Cu}^{2+}$ , resulting from the reducing capability of TA toward  $\text{Cu}^{2+}$  during coordination [31]. Ga was primarily present as  $\text{Ga}^{3+}$ , and the Zn 2p spectrum corresponded to  $\text{Zn}^{2+}$  (Figure 1J, K).


Similar to other metal-polyphenol network nanozymes, the mixed valence states of  $\text{Cu}^+/\text{Cu}^{2+}$  in ZTCG mimic the electron redox behavior of natural enzymes, thereby endowing them with nanozyme characteristics [32, 33]. Meanwhile, its MPN structure exhibits ROS-responsive degradation capability, enabling on-demand therapy (Figure 1L). This process produced two biological effects. On the one hand, it can quickly scavenge excess ROS, effectively reducing oxidative stress in the wound microenvironment. On the other hand, it facilitates the release of TA,  $\text{Cu}^{2+}$ , and  $\text{Ga}^{3+}$ , which collectively exert antibacterial, anti-inflammatory, and tissue-repair-promoting effects. To verify the ROS-responsive degradation behavior of this coating, we examined the cumulative release profiles of  $\text{Cu}^{2+}$ ,  $\text{Ga}^{3+}$ , and TA under high oxidative stress conditions ( $300\text{ }\mu\text{M H}_2\text{O}_2$ ) and simulated physiological conditions (PBS). As shown in Figure 1M and 1N, ion release was slow with low

cumulative amounts in PBS, whereas the release of both  $\text{Cu}^{2+}$  and  $\text{Ga}^{3+}$  was significantly increased in the  $\text{H}_2\text{O}_2$  environment. A similar release behavior was observed for TA (Figure 1O). These results demonstrate that ZTCG nanozymes possess excellent ROS-responsive characteristics, enabling the release of therapeutic factors on demand based on the ROS levels in diabetic chronic wounds.


### Multi-enzyme activities and free radical scavenging capacity of ZTCG nanozymes

The elevated ROS levels in the diabetic wound

microenvironment disrupt redox homeostasis, leading to significant cellular damage and impaired wound healing [34]. A key therapeutic strategy currently involves the use of exogenous nanozymes to scavenge excess ROS and restore redox balance. As illustrated in **Figure 2A**, ZTCG nanozymes not only effectively eliminate  $\cdot\text{O}_2^-$  and  $\text{H}_2\text{O}_2$  through their CAT-like and SOD-like activities, but also directly scavenge various free radicals, including  $\cdot\text{OH}$ ,  $\text{ABTS}\cdot$ , and  $\text{DPPH}\cdot$ .



**Figure 1. Preparation and characterization of ZTCG nanozymes.** (A, B) TEM and SEM images of ZIF-8, ZT, and ZTCG. (C) Elemental mapping of ZTCG nanozymes. (D) DLS measurements. (E) Zeta potential analysis ( $n = 3$ ). (F) XRD patterns. (G) FTIR spectra. (H) XPS survey spectrum of ZTCG nanozymes. (I-K) XPS analysis of Cu 2p, Ga 3d, and Zn 2p in ZTCG nanozymes. (L) Schematic diagram of the ROS-responsive release of ZTCG nanozymes. (M-O) Release profiles of TA,  $\text{Ga}^{3+}$ , and  $\text{Cu}^{2+}$  from ZTCG with or without  $\text{H}_2\text{O}_2$  treatment. Values are expressed as the mean  $\pm$  SD.



**Figure 2. Multi-enzyme activities and antioxidant capacity of ZTCG nanozymes.** (A) Proposed scavenging mechanisms of ZTCG nanozymes against various free radicals. (B–D) ESR spectroscopy of ZTCG for  $\cdot\text{OH}$ ,  $^1\text{O}_2$ , and  $\cdot\text{O}_2^-$ . (E, F)  $\cdot\text{OH}$  scavenging profile (E) and corresponding scavenging efficiency (F) of ZTCG nanozymes. (G, H) Scavenging efficiency of ZTCG nanozymes against ABTS $\cdot$  (G) and DPPH $\cdot$  (H). (I, J)  $\cdot\text{O}_2^-$  scavenging profile (I) and scavenging efficiency (J) of ZTCG nanozymes. (K, L) H<sub>2</sub>O<sub>2</sub> scavenging profile (K) and scavenging efficiency (L) of ZTCG nanozymes. (M) O<sub>2</sub> generation curve of ZTCG nanozymes. (N) CV curves of ZTCG with and without H<sub>2</sub>O<sub>2</sub>. (O) Radar chart illustrating the multi-enzyme activities and radical scavenging capacity of ZTCG nanozymes at various concentrations. Values are expressed as the mean  $\pm$  SD. (n = 3).

ESR results clearly showed that the ZTCG nanozymes effectively eliminated  $\cdot\text{OH}$ ,  $^1\text{O}_2$ , and  $\cdot\text{O}_2^-$  (Figure 2B–D). We further employed a salicylic acid capture assay to quantitatively measure the removal of  $\cdot\text{OH}$ . In this assay,  $\cdot\text{OH}$  radicals oxidize salicylic acid to produce 2,3-dihydroxybenzoic acid, which has a distinct light absorption peak at 510 nm [35]. After adding the ZTCG nanozymes, the absorbance at 510 nm decreased sharply in a concentration-dependent manner (Figure 2E). At 200  $\mu\text{g}/\text{mL}$ , ZTCG nanozymes achieved a  $\cdot\text{OH}$  scavenging rate of  $23.70 \pm 0.85\%$  (Figure 2F).

The broad-spectrum radical scavenging ability of ZTCG nanozymes was evaluated using DPPH $\cdot$  and ABTS $\cdot$  assay kits. In the ABTS $\cdot$  assay, after treatment with ZTCG nanozymes, the solution changed from bluish-green to colorless. At 200  $\mu\text{g}/\text{mL}$ , the ABTS $\cdot$

scavenging rate of ZTCG reached  $75.47 \pm 0.86\%$  (Figure 2G). Similarly, after 15 min of co-incubation, ZTCG nanozymes scavenged  $59.84 \pm 0.45\%$  of DPPH $\cdot$  at the same concentration, accompanied by a color change from purple to yellow (Figure 2H). These results confirm the excellent free radical scavenging capacity of ZTCG nanozymes.

SOD is one of the key antioxidant enzymes within cells. To investigate the SOD-like activity of ZTCG nanozymes, the NBT photoreduction method was used. Under UV radiation,  $\cdot\text{O}_2^-$  generated from riboflavin and methionine converts colorless NBT to blue formazan, which exhibits maximal absorbance at 560 nm [35]. The addition of ZTCG nanozymes significantly decreased the absorbance of the solution (Figure 2I). The inhibition rate against  $\cdot\text{O}_2^-$  exceeded  $67.66 \pm 0.07\%$  at a ZTCG nanozyme concentration of

25  $\mu\text{g}/\text{mL}$ , demonstrating excellent SOD-like activity (Figure 2J).

The primary source of oxidative damage in biological systems is  $\text{H}_2\text{O}_2$ , which is broken down by the vital enzyme catalase [36]. We evaluated the  $\text{H}_2\text{O}_2$  scavenging ability of ZTCG nanozymes using a hydrogen peroxide assay kit. A dose-responsive reduction in absorbance at 410 nm was observed with increasing ZTCG concentrations (Figure 2K, L). Most impressively, at 200  $\mu\text{g}/\text{mL}$ , ZTCG nanozymes achieved a remarkable  $\text{H}_2\text{O}_2$  scavenging rate of  $87.75 \pm 0.25\%$ , confirming their broad ROS scavenging activity. Oxygen is a common product following the SOD/CAT-mimicking activities of nanozymes. To monitor the oxygen generation capacity of ZTCG nanozymes, we performed real-time detection using a dissolved oxygen meter. After incubating different concentrations of ZTCG nanozymes with 1 mM  $\text{H}_2\text{O}_2$  at room temperature, oxygen production increased continuously over time and with increasing nanozyme concentration. At 200  $\mu\text{g}/\text{mL}$ , the dissolved oxygen concentration reached 12.54 mg/L within 300 s, whereas almost no oxygen release was detected at 0  $\mu\text{g}/\text{mL}$  (Figure 2M and Figure S3). Subsequently, the Michaelis-Menten saturation curve for steady-state kinetic measurements was fitted using varying concentrations of  $\text{H}_2\text{O}_2$  as the substrate. According to the Lineweaver-Burk plot, the maximum reaction velocity ( $V_{\text{max}}$ ) and Michaelis-Menten constant ( $K_{\text{m}}$ ) were determined to be 1.26  $\text{mg L}^{-1} \text{min}^{-1}$  and 70.52 mM, respectively, as shown in Figure S4. Based on these kinetic parameters, the CAT-like catalytic activity of the ZTCG nanozymes is higher than those of previously reported nanozymes [37, 38].

To further investigate its CAT-like activity, the electrocatalytic behavior of ZTCG towards  $\text{H}_2\text{O}_2$  was measured using cyclic voltammetry. Figure 2N shows the cyclic voltammetry curves of the ZTCG-modified electrode in PBS with and without 3 mM  $\text{H}_2\text{O}_2$ . Upon the addition of  $\text{H}_2\text{O}_2$ , the reduction current increased significantly starting from approximately -1 V. Concurrently, the anodic current around 0.65 V also increased. This increase in electron transfer efficiency upon  $\text{H}_2\text{O}_2$  addition demonstrates the compound's potent catalase-like catalytic activity.

As shown in Figure 2O, the multi-enzyme catalytic actions of the ZTCG nanozymes show a clear concentration dependence. This multi-enzymatic catalysis not only exhibits outstanding scavenging activity against various ROS but also reduces local hypoxia in the wound through *in situ* oxygen delivery, offering twofold assurance in reducing cellular oxidative damage and fostering wound healing.

## Antibacterial and anti-biofilm activity of ZTCG nanozymes


Due to impaired immune function, diabetic wounds are particularly vulnerable to recurrent pathogenic bacterial infections and biofilm formation, which can lead to drug resistance and ultimately result in refractory wound healing [39]. To evaluate the broad-spectrum antibacterial performance of the ZTCG nanozymes, *MRSA* and *E. coli* were used as model strains. The antibacterial activity was determined by the plate count method. As shown in Figure 3A, the number of bacterial colonies for both strains decreased significantly with increasing concentrations of the ZTCG nanozymes. At 200  $\mu\text{g}/\text{mL}$ , the antibacterial rates against *MRSA* and *E. coli* reached  $98.55 \pm 0.71\%$  and  $99.37 \pm 0.21\%$ , respectively (Figure 3B, C). These results demonstrate that ZTCG nanozymes possess a highly effective, broad-spectrum antibacterial capability.

One important mechanism of bacterial drug resistance is the production of biofilms. Live/dead bacterial fluorescence staining and the crystal violet staining technique were used to further explore the anti-biofilm activity of ZTCG nanozymes *in vitro*. Crystal violet staining results showed that the biofilm structure remained intact at 0  $\mu\text{g}/\text{mL}$  but became severely disrupted with increasing ZTCG nanozyme concentrations (Figure 3D). At 200  $\mu\text{g}/\text{mL}$ , the biofilm eradication rates reached  $84.14 \pm 0.66\%$  and  $78.47 \pm 0.44\%$  for *MRSA* and *E. coli*, respectively (Figure 3E, F). CLSM observations were highly consistent with these results. Biofilms with a high density of live bacteria (green fluorescence) persisted at 0  $\mu\text{g}/\text{mL}$ . Treatment with low concentrations of ZTCG nanozymes caused partial biofilm damage and an increase in dead bacteria (red fluorescence). When the concentration was increased to 100  $\mu\text{g}/\text{mL}$ , the biofilms were completely destroyed, and nearly no live bacteria were observed in the field of view (Figure 3G). These results clearly demonstrate the exceptional performance of ZTCG nanozymes in eradicating biofilms. Further SEM analysis showed that as the ZTCG nanozymes concentration increased, bacterial cell membranes became visibly ruptured and shrunken, with evidence of intracellular content leakage (Figure 3G).

To better understand the antibacterial mechanism, *MRSA* was used as the model bacterium. TEM observations (Figure 3H) showed that untreated control bacteria maintained their structural integrity and exhibited uniformly distributed intracellular material. In contrast, after treatment with ZTCG nanozymes, bacterial membranes were severely damaged, accompanied by the outflow of cytoplasmic contents. These findings suggest that the antibacterial

action might be related to bacterial membrane damage. This hypothesis was confirmed using the fluorescent probe DiSC<sub>3</sub> to detect changes in bacterial membrane potential [40]. The fluorescence intensity increased significantly with higher ZTCG nanozymes concentration, indicating that the nanozymes induced bacterial membrane depolarization (Figure 3I). Furthermore, the ONPG hydrolysis experiment was

used to assess the bacterial membrane permeability [41]. The amount of ONPG hydrolysis increased with rising ZTCG nanozymes concentrations (Figure 3J), confirming that the nanozymes enhance bacterial membrane permeability. Further evidence of reduced membrane integrity was provided by increased protein leakage in the bacterial culture supernatant (Figure 3K).



**Figure 3. Antibacterial and anti-biofilm activity of ZTCG nanozymes.** (A) Colony images of *MRSA* and *E. coli* after treatment with ZTCG nanozymes. (B, C) Antibacterial rates of ZTCG nanozymes against *MRSA* (B) and *E. coli* (C). (D) Crystal violet-stained images of bacterial biofilms (*MRSA* and *E. coli*) after treatment with ZTCG nanozymes. (E, F) Quantitative analysis of biofilm eradication. (G) Fluorescence staining images and SEM images of different bacterial biofilms after treatment with ZTCG nanozymes (yellow arrows indicate dead bacteria). (H) TEM images of *MRSA* and *E. coli* after treatment with PBS or ZTCG nanozymes (blue arrows indicate damaged sites of the bacterial cell membrane). (I) Bacterial membrane potential staining of *MRSA* after treatment with ZTCG nanozymes. (J) Quantitative analysis of membrane permeability. (K) Quantitative analysis of protein leakage. Values are expressed as the mean  $\pm$  SD. (n = 3). \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001.

In summary, the antibacterial mechanism of the ZTCG nanozyme is primarily attributed to membrane disruption, leading to membrane depolarization and increased permeability, which consequently causes leakage of essential intracellular components, such as proteins, ultimately achieving a potent bactericidal effect.

### **Fabrication and characterization of the bilayer microneedle and its H<sub>2</sub>O<sub>2</sub> visual monitoring capability**

A cerium-based MOF (Ce-MOF) was synthesized by adopting a previously reported approach with optimization (Figure 4A) [27]. SEM results showed that the pristine Ce-MOF exhibited a flower-like structure, while after being treated with H<sub>2</sub>O<sub>2</sub>, the OXCe-MOF transformed into a rod-like structure (Figure 4B). EDS analysis confirmed that Ce, O, and C elements were uniformly distributed in Ce-MOF (Figure 4C). High-resolution XPS spectra revealed that Ce in the pristine Ce-MOF existed primarily in the Ce<sup>3+</sup> state. Following H<sub>2</sub>O<sub>2</sub> treatment, the Ce<sup>4+</sup>/Ce<sup>3+</sup> ratio in OXCe-MOF significantly increased (Figure 4D, E), and its color turned yellow (Figure S5), suggesting a strong colorimetric response of Ce-MOF to H<sub>2</sub>O<sub>2</sub>. We evaluated the selectivity of the colorimetric response of Ce-MOF against a panel of potential interferents commonly present in the wound microenvironment. As shown in Figure S6, the Ce-MOF exhibited a distinct and significant colorimetric response only in the presence of H<sub>2</sub>O<sub>2</sub>. In contrast, no notable color change was observed upon exposure to water, acidic conditions (pH 5.5), potassium chloride (KCl), sodium chloride (NaCl), glucose, uric acid (UA), ascorbic acid (AA), or L-lysine. These results confirm the high selectivity of the Ce-MOF sensing layer toward H<sub>2</sub>O<sub>2</sub>, supporting its suitability for specific oxidative stress monitoring in complex wound exudate environments.


The bilayer MNs@Z/CP patch was fabricated via a template casting method. The needle layer consisted of a HAMA hydrogel loaded with ZTCG nanozymes (MNs@Z) for antibacterial and ROS-scavenging purposes. The backing layer was made of an electrospun PCL membrane spray-coated with Ce-MOF (CP layer), which served as the colorimetric component (Figure 4F). Macroscopically, the patch exhibited a bilayer structure consisting of a well-defined brown microneedle layer and a white backing layer (Figure 4G). Cross-sectional SEM views of the needle indicated a height of 600 μm and a base diameter of 360 μm (Figure 4G). The electrospun fiber surface displayed uniformly distributed Ce-MOF particles, as verified by SEM and EDS (Figure 4G and Figure S7). Mechanical compression tests showed that

a force of 10.29 ± 2.79 N was required at a compression displacement of 0.6 mm (Figure 4H, I), demonstrating sufficient mechanical strength for skin insertion without fracture [42]. The minimally invasive nature was demonstrated by *in situ* implantation tests on a rat skin model, which revealed full epidermal penetration with distinct needle holes after insertion, followed by progressive tissue healing and pore closure (Figure 4J). According to the drug release experiment shown in Figure S8, Ga<sup>3+</sup> and Cu<sup>2+</sup> were continuously released from the microneedles, thereby achieving the therapeutic effect.

When Ce<sup>3+</sup> is oxidized to Ce<sup>4+</sup>, the color of Ce-MOF transitions from white to yellow, and the color intensity is positively correlated with the concentration of H<sub>2</sub>O<sub>2</sub> [27]. CP films were immersed in H<sub>2</sub>O<sub>2</sub> solutions at different concentrations to measure this response and ImageJ software was used to extract RGB values from optical images (Figure 4K). The regression equation  $R/G = 0.02802 \times \text{H}_2\text{O}_2 \text{ (mmol/L)} + 0.9869$  describes the good linear relationship between H<sub>2</sub>O<sub>2</sub> concentration and the R/G value, which allowed for the creation of a standard color chart (Figure 4L, M). Using this equation and color chart, semi-quantitative assessment of wound H<sub>2</sub>O<sub>2</sub> levels becomes feasible. In animal studies, application of MNs@Z/CP to diabetic wounds induced a visible color change (Figure 4N), whereas the control group without Ce-MOF coating showed no such response. Moreover, no color change was observed when MNs@Z/CP was applied to normal wounds. This color change is attributed to the elevated H<sub>2</sub>O<sub>2</sub> levels in the diabetic wound microenvironment resulting from inflammation and hyperglycemia. These findings show that MNs@Z/CP can visually monitor wound H<sub>2</sub>O<sub>2</sub>. Based on the color change of MNs@Z/CP, the next steps in the treatment plan, such as whether to replace the patch, can be determined. Compared with conventional nanozyme microneedles that are limited to a single therapeutic function [43–45], the key advantage of MNs@Z/CP lies in its dual-function capability for both treatment and monitoring, enabling precise adjustment of therapeutic strategies based on real-time monitoring outcomes. Before treatment and on days 3 and 5 after MNs@Z/CP treatment, we measured the H<sub>2</sub>O<sub>2</sub> concentration in wounds of diabetic rats using a colorimetric method. As shown in Figure S9, the color of the MNs@Z/CP microneedles gradually faded on days 3 and 5 post-treatment, and the corresponding mean RGB values were obtained according to the established relationship. The results indicated that due to MNs@Z/CP treatment, wound inflammation and oxidative stress were alleviated, leading to a gradual decrease in H<sub>2</sub>O<sub>2</sub> concentration.

Subsequently, we further measured the wound  $H_2O_2$  levels of rats using an  $H_2O_2$  assay kit, and the results were highly consistent with those obtained from the microneedle monitoring (Figure S10). Collectively,

these findings demonstrate that the microneedles can effectively monitor wound  $H_2O_2$  concentration via colorimetric analysis.



**Figure 4. Physical characterization and  $H_2O_2$ -responsive colorimetric properties of MNs@Z/CP.** (A) Schematic diagram of the preparation of Ce-MOF and its  $H_2O_2$ -responsive color transition. (B) SEM images of Ce-MOF and OXCe-MOF. (C) EDS images of Ce-MOF. (D) XPS spectra of Ce-MOF and OXCe-MOF. (E) Ce 3d XPS spectra of Ce-MOF and OXCe-MOF. (F) Schematic diagram illustrating the fabrication of MNs@Z/CP and its  $H_2O_2$ -triggered color transition. (G) Photographs and SEM images of the backing layer (CP electrospun membrane) and microneedle array. (H, I) Stress-displacement curve (H) and quantification (I) of MNs@Z/CP. (J) Photos of MNs@Z/CP penetrating rat skin at 0–15 min. (K)  $H_2O_2$ -responsive colorimetric transition of the CP electrospun membrane and corresponding quantitative RGB (Red, Green, Blue) analysis. (L, M) R/G (red/green) value and  $H_2O_2$  concentration curve (L) and linear correlation analysis (M). (N) Color changes of MNs@Z/CP before and after application on diabetic and normal wound.

A fundamental requirement for biomedical applications is excellent biocompatibility [15]. Initially, we evaluated the biocompatibility of the ZTCG nanozymes through hemolysis assay, CCK-8 assay, and live/dead staining. Compared with ZIF-8, the MPN-coated ZTCG nanozymes exhibited improved biocompatibility (Figure S11). CCK-8 assays validated that ZTCG nanozymes were significantly less cytotoxic than ZIF-8 at 200  $\mu\text{g}/\text{mL}$  (Figure S12). Furthermore, the hemolysis rate of ZTCG nanozymes was below 5% at concentrations up to 200  $\mu\text{g}/\text{mL}$  but exceeded this threshold at 400  $\mu\text{g}/\text{mL}$  (Figure S13). Consequently, the 200  $\mu\text{g}/\text{mL}$  concentration was selected for microneedle preparation.

We further evaluated the cytotoxicity of the fabricated materials (MNs/P, MnS@Z/P, and MnS@Z/CP) towards HUVECs and L929 cells. After co-culture, cell viability of all material groups remained above 90% (Figure S14), suggesting high biosafety. Live/dead staining provided additional evidence for this conclusion (Figure S15). Moreover, the hemolysis experiment verified that all bilayer microneedles exhibited a hemolysis rate below 5% (Figure S16). While considerable breakage was seen in the positive group, microneedle-treated erythrocytes retained structural integrity, similar to the PBS group (Figure S16). Collectively, these findings demonstrate that MnS@Z/CP possesses outstanding biocompatibility, offering a strong basis for its *in vivo* application.

We also evaluated the anti-inflammatory and antibacterial properties of MnS@Z/CP *in vitro*. Owing to the addition of ZTCG nanozymes, both MnS@Z/P and MnS@Z/CP had improved ABTS $\cdot$  and DPPH $\cdot$  scavenging capabilities, with MnS@Z/CP demonstrating more potent free radical elimination capability (Figure S17). At the same time, MnS@Z/P and MnS@Z/CP showed strong antibacterial activity against MRSA and *E. coli* (Figure S18). Notably, MnS@Z/CP demonstrated higher anti-inflammatory and antibacterial efficacy than MnS@Z/P, which can be attributed to the synergistic effect of the integrated Ce-MOF's inherent antibacterial properties and radical scavenging capacity.


### **MnS@Z/CP promotes cell proliferation, migration, and angiogenesis by alleviating oxidative stress *in vitro***

Non-enzymatic protein glycation leads to considerable accumulation of advanced glycation end products (AGEs) in diabetes. By triggering the

AGEs-RAGE signaling pathway, AGEs not only directly induce oxidative stress but also synergistically elevate intracellular ROS levels [46]. These changes result in a persistently inflamed wound microenvironment, severely impeding the healing process. We further assessed the capacity of the MnS@Z/CP bilayer microneedles to scavenge ROS, reduce oxidative stress, and preserve cell viability *in vitro*.

First, we investigated the cytoprotective effect of MnS@Z/CP against H<sub>2</sub>O<sub>2</sub>-induced oxidative stress. Live/dead cell labeling and CCK-8 tests showed that H<sub>2</sub>O<sub>2</sub> treatment dramatically decreased the viability of both L929 cells and HUVECs. In contrast, treatment with either MnS@Z/P or MnS@Z/CP effectively reversed this trend, significantly improving cell survival under oxidative stress (Figure 5A-C). DCFH-DA staining was used to measure intracellular ROS levels. H<sub>2</sub>O<sub>2</sub> treatment markedly increased intracellular ROS, as seen in Figure 5D and E, whereas both MnS@Z/P and MnS@Z/CP treatments reduced this H<sub>2</sub>O<sub>2</sub>-induced ROS elevation. EdU assays further demonstrated that MnS@Z/CP effectively maintained cell proliferation activity after H<sub>2</sub>O<sub>2</sub> exposure (Figure 5F, G). These findings confirm the excellent ROS-scavenging ability of MnS@Z/CP and its corresponding cytoprotective function.

Coordinated cellular processes, such as fibroblast-driven granulation and endothelial-mediated angiogenesis, are necessary for diabetic wound healing. The persistent oxidative stress frequently interferes with these processes [47]. We further evaluated the effects of MnS@Z/CP on cell migration and angiogenesis under oxidative stress conditions. In the scratch assay, fibroblast migration was impaired in the H<sub>2</sub>O<sub>2</sub> group, whereas MnS@Z/CP significantly enhanced fibroblast migration, achieving an  $84.43 \pm 3.78\%$  wound closure rate (Figure 5H, I). Tube formation assays demonstrated that MnS@Z/CP reversed the H<sub>2</sub>O<sub>2</sub>-induced disruption of tubular structures, leading to the formation of a dense and interconnected tube network (Figure 5J). Quantitative analysis further confirmed the superior pro-angiogenic activity of MnS@Z/CP under oxidative stress conditions (Figure 5K-M). This study demonstrates that MnS@Z/CP effectively protects cells from oxidative damage by scavenging ROS. As a result, it increases the angiogenic capacity of endothelial cells, promotes fibroblast migration and proliferation under inflammatory conditions, and accelerates diabetic wound healing.



**Figure 5.** MNs@Z/CP promotes cell proliferation, migration, and tube formation under inflammatory conditions *in vitro*. (A) Live/dead staining images after different treatments. (B, C) Cell viability of L929 cells (B) and HUVECs (C) after different treatments. (D, E) Scavenging capacity of MNs@Z/CP against H<sub>2</sub>O<sub>2</sub>-induced ROS assessed by DCFH-DA staining (D) and its quantitative analysis (E). (F, G) Immunofluorescence images of EdU staining (F) and its quantification (G) in L929 cells (n = 5). (H) Images illustrating scratch wound healing (n = 3). (I) Quantification of the scratch assay (n = 3). (J) Tube formation images after different treatments. (K-M) Quantification of the number of nodes (K), junctions (L), and meshes (M) (n = 3). Values are expressed as the mean ± SD. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001.

### MNs@Z/CP induces macrophage reprogramming by activating the Nrf2/HO-1 pathway

We further investigated the underlying antioxidant mechanisms of MNs@Z/CP at the cellular level (Figure 6A). DCFH-DA fluorescence images showed that LPS stimulation significantly increased green fluorescence in macrophages, indicating elevated ROS levels (Figure 6B). Treatment with MNs@Z/P and MNs@Z/CP effectively scavenged intracellular ROS, resulting in a marked reduction in green fluorescence. Flow cytometry quantification confirmed that ROS levels in the MNs@Z/CP group were significantly lower than in all other treatment groups (Figure 6C).

Given the critical role of ROS in mitochondrial function, we subsequently measured changes in  $\Delta\Psi_m$  using JC-1 staining (Figure 6D). The findings demonstrated that LPS treatment reduced  $\Delta\Psi_m$ , indicating compromised mitochondrial activity. In contrast, both MNs@Z/P and MNs@Z/CP significantly restored  $\Delta\Psi_m$ , with the MNs@Z/CP group showing the strongest effect. Quantitative flow cytometry results (Figure 6E) further verified that the treatment effectively mitigated LPS-induced mitochondrial dysfunction.

Macrophage polarization is directly linked to the healing process of diabetic ulcers [48, 49]. We subsequently explored whether MNs@Z/CP could remodel immune homeostasis by reprogramming macrophages. Theoretically, reducing intracellular ROS levels facilitates the polarization of macrophages towards the M2 phenotype. Immunofluorescence staining (Figure 6F) showed that MNs@Z/P and MNs@Z/CP treatments significantly upregulated CD206 (M2 marker, green fluorescence) expression, while suppressing iNOS (M1 marker, red fluorescence). RT-qPCR results (Figure 6G) indicated that MNs@Z/P and MNs@Z/CP effectively counteracted the LPS-induced upregulation of pro-inflammatory genes (*IL-6*, *iNOS*, *TNF- $\alpha$* ) and concurrently promoted the expression of M2-associated anti-inflammatory mediators (*IL-10*, *CD206*). WB analysis (Figure 6H) further demonstrated that the MNs@Z/P and MNs@Z/CP treatments shifted macrophage polarization toward the M2 phenotype. Notably, MNs@Z/CP exhibited superior cytoprotective, ROS scavenging, and M2-polarizing capabilities compared to MNs@Z/P. The superior performance of MNs@Z/CP may be ascribed to the combined action of Ce-MOF and ZTCG nanozymes, which synergistically improve therapeutic efficacy. In addition to the intrinsic activity of ZTCG, Ce-MOF utilizes the variable

valence states of cerium ions ( $\text{Ce}^{3+}/\text{Ce}^{4+}$ ) to scavenging free radicals via electron transfer interactions [50], thereby further alleviating oxidative stress and promoting microenvironmental remodeling.

The Nrf2/HO-1 signaling axis is essential for reducing oxidative stress, wherein Nrf2 exerts cytoprotective antioxidant effects mainly by upregulating the downstream effector HO-1 [51, 52]. We further investigated the impact of MNs@Z/CP on the Nrf2/HO-1 pathway to elucidate its anti-inflammatory mechanism. Immunofluorescence analysis revealed that LPS treatment downregulated Nrf2 and HO-1 expression, whereas MNs@Z/CP treatment significantly enhanced the intracellular intensity of both Nrf2 and HO-1 (Figure 6I). Based on these findings, we hypothesized that MNs@Z/CP may promote macrophage reprogramming by activating the Nrf2/HO-1 pathway. To validate this process, we conducted further mechanistic studies (Figure 6J-L). RT-qPCR results demonstrated that LPS suppressed the expression of *Keap1*, *Nrf2*, *HO-1*, and *CAT* in macrophages, while MNs@Z/CP treatment upregulated the expression of these genes (Figure 6J). Consistent WB data also showed that MNs@Z/CP therapy decreased the protein level of NOX1, a significant ROS producer. We speculate that this decrease in NOX1 protein levels results from macrophage polarization toward the M2 phenotype, which lowers inflammation and subsequently suppresses NOX1 production via feedback mechanism. Downregulation of NOX1 would further decrease intracellular ROS levels, establishing a positive feedback regulatory loop (Figure 6K, L).


In summary, MNs@Z/CP alleviates mitochondrial dysfunction and reprograms macrophages toward the M2 phenotype by activating the intrinsic Keap1/Nrf2/HO-1 antioxidant cascade, thereby creating a microenvironment conducive to tissue healing.

### MNs@Z/CP promotes the healing of diabetic wounds


To systematically evaluate the therapeutic performance of the MNs@Z/CP patch, a STZ-induced diabetic rat model was used (Figure 7A) [4]. Wounds were observed and captured on days 0, 3, 7, and 12 post-treatments (Figure 7B, C). Compared with the blank and MNs/P groups, accelerated wound contraction was evident in the MNs@Z/P and MNs@Z/CP groups as soon as day 3. Notably, the MNs@Z/CP group showed a wound closure rate of  $53.32 \pm 2.73\%$  on day 7, higher than that of any other group. By day 12, the MNs@Z/P group exhibited a closure rate of  $74.15 \pm 1.21\%$ , whereas the blank and

MNs/P groups still had substantial unhealed wound areas (closure rates of  $63.34 \pm 4.89\%$  and  $64.84 \pm 2.07\%$ , respectively). In contrast, the MNs@Z/CP group

achieved a closure rate of  $83.17 \pm 1.66\%$  on day 12, representing the most complete wound closure (Figure 7D, E).



**Figure 6. MNs@Z/CP reprograms macrophages via the Nrf2/HO-1 pathway in vitro.** (A) Schematic diagram elucidating the proposed mechanism of macrophage reprogramming. (B) DCFH-DA staining images. (C) Flow cytometry of intracellular ROS. (D) ΔΨm assessment using JC-1 staining and flow cytometry analysis. (E) Quantitative analysis of JC-1 staining. (F) Immunofluorescence images of iNOS and CD206 in macrophages. (G) RT-qPCR analysis of mRNA levels for *IL-6*, *TNF-α*, *iNOS*, *IL-10*, and *CD206*. (H) Western blot of CD206 and iNOS protein levels and quantitative bubble plot. (I) Fluorescence images of Nrf2 and HO-1 in macrophages. (J) RT-qPCR analysis of mRNA levels for *Nrf2*, *Keap1*, *HO-1*, and *CAT*. (K) Western blot analysis of Nrf2, Keap1, NOX1, HO-1, and CAT. (L) Corresponding quantitative bubble plot. Values are expressed as the mean ± SD. (n = 3). \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001.



**Figure 7. Therapeutic efficacy of MNs@Z/CP in diabetic wounds.** (A) Experimental schematic of establishing diabetic wounds. (B) Representative photographs of wound healing process in the blank, MNs/P, MNs@Z/P, and MNs@Z/CP groups. (C) Wound traces in each group. (D) Wound closure rate curve. (E) Wound closure rate on day 12. (F, G) H&E (F) and Masson (G) staining images. (H, I) Immunofluorescence staining images for iNOS and CD206 of wound tissues. (J) Immunofluorescence staining images for α-SMA and CD31 of wound tissues. (K-N) Quantified areas positive for α-SMA (K), CD31 (L), CD206 (M), and iNOS (N). Values are expressed as the mean ± SD. (n = 5). \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001.

On day 12, we harvested the wound sites and adjacent skin tissues for histological assessment. H&E staining (Figure 7F) indicated that the wound in the MNs@Z/CP group was almost entirely covered by

epithelial tissue, with intact epidermal regeneration and densely packed granulation tissue. In contrast, both the blank and the MNs/P groups still exhibited scab formation and inflammatory cell infiltration.

Granulation tissue formed in the MNs@Z/P group but remained immature, and epidermal regeneration was insufficient. These results demonstrate that MNs@Z/CP therapy successfully reduced inflammation and promoted wound healing.

### **MNs@Z/CP promotes collagen deposition, angiogenesis, and macrophage reprogramming in diabetic wounds**

Optimal wound healing quality is critically dependent upon adequate collagen deposition, which provides essential support for tissue remodeling, cell proliferation, and differentiation [53]. Masson's trichrome staining (Figure 7G, J) demonstrated that the MNs@Z/CP group exhibited the most abundant and well-organized collagen deposition. CD31 is a marker of nascent endothelial cells during early angiogenesis, while  $\alpha$ -SMA indicates vascular maturity and pericyte recruitment [54, 55]. Therefore, angiogenesis was assessed by immunofluorescence staining for CD31 and  $\alpha$ -SMA. The blank group displayed only weak positive signals (Figure 7H). Within the wound region, CD31 and  $\alpha$ -SMA expression were markedly increased in the MNs@Z/P group and were most intense in the MNs@Z/CP group, indicating the superior pro-angiogenic capacity of the MNs@Z/CP group (Figure 7K, L).

During wound healing, macrophages are essential for immune regulation [56]. The delayed M1 to M2 transition of macrophages impairs tissue regeneration in diabetic wounds. Using immunofluorescence labeling, we evaluated the expression of iNOS and CD206. As illustrated in Figure 7I, MNs@Z/CP treatment significantly decreased the iNOS-positive area while increasing the CD206-positive area compared with the blank group. Specifically, the MNs@Z/CP group showed the lowest iNOS expression and the highest level of CD206 expression (Figure 7M, N), suggesting that this therapy successfully promoted macrophage reprogramming toward the M2 phenotype.

In summary, the bilayer MNs@Z/CP patch promotes macrophage phenotypic shift, enhances collagen deposition and angiogenesis, synergistically inhibits the inflammatory response, and accelerates tissue remodeling to enable rapid and high-quality healing of diabetic wounds.

### **MNs@Z/CP targets the IL-17 signaling pathway and cell cycle to remodel the diabetic wound microenvironment**

Although MNs@Z/CP has shown promising therapeutic outcomes, a comprehensive understanding of its anti-inflammatory and tissue remodeling mechanisms is lacking. We performed


transcriptomic sequencing analysis on rat wound tissues from the MNs@Z/CP-treated and blank groups 12 days post-treatment. The volcano plot illustrated significant differential gene expression (Figure 8A), and Venn analysis identified 4043 differentially expressed genes (DEGs) (Figure 8B). Unsupervised clustering analysis indicated clear separation between the two groups (Figure 8C), suggesting that MNs@Z/CP exerts a global regulatory effect on the wound healing transcriptome.

To characterize the biological processes associated with these DEGs, we performed KEGG and GO enrichment analysis. GO analysis showed that the DEGs were predominantly enriched in immune response regulation and cell cycle-related processes (Figure 8D), providing a molecular basis for the immune modulation and repair promotion mediated by MNs@Z/CP. KEGG pathway analysis further showed that MNs@Z/CP treatment was strongly associated with activation of the cell cycle pathway and downregulation of the IL-17 signaling pathway and natural killer cell-mediated cytotoxicity pathway (Figure 8E, F). Previous studies have shown that ROS activates the IL-17 pathway, triggering a pro-inflammatory cascade that releases TNF- $\alpha$ , CCL2, and IL-1 $\beta$  [57, 58]. This leads to M1 macrophage polarization and neutrophil recruitment and activation, thereby exacerbating local inflammation. These factors can worsen oxidative stress, inhibit cell division, and cause cell death, ultimately impairing diabetic wound healing [9, 59]. Herein, MNs@Z/CP effectively suppressed the IL-17 signaling pathway, thereby reducing inflammation, promoting macrophage transition toward the M2 phenotype, and establishing a pro-regenerative cytokine milieu that synergizes with cell cycle progression to accelerate wound healing.

To validate these enrichment analysis results, we used gene set enrichment analysis (GSEA) on the "immune response" (GO), "IL-17 signaling pathway" (KEGG), "cell killing" (GO), and "Cell Cycle" (KEGG) pathways (Figure 8G-J). GSEA results indicated an overall suppression of the immune response and the IL-17 pathway in the treated group (Figure 8H). This finding is significant because the IL-17 cytokine, which is chronically overexpressed in diabetic wounds, exacerbates tissue damage by inducing matrix metalloproteinases that degrade the extracellular matrix and disrupt cell-matrix adhesion [60]. Our data confirmed the downregulation of specific pathway components, including *IL1R1*, *IL17RA*, *IL17A*, and the downstream genes *FOSL1* and *S100A9* (Figure 8K, L and Figure S19). Concurrently, GSEA revealed that MNs@Z/CP inhibited cell killing-related pathways while promoting cell cycle

progression. Ki-67, a nuclear protein widely used as a marker for active cell cycle phases, directly reflects tissue proliferative status [61]. In this study, Ki67 expression was significantly upregulated in the MNs@Z/CP-treated group, as were mitosis-associated genes such as *NDC80*, *SGO1*, and *KNL1* (Figure 8M, N and Figure S20). Furthermore, immunohistochemical staining for IL-17 and immunofluorescence staining for Ki67 further confirmed these findings. The blank group still exhibited high levels of IL-17 expression on day 12,

indicating persistent inflammation (Figure 8O and Figure S21). In contrast, MNs@Z/CP treatment significantly reduced IL-17 levels, with the MNs@Z/P group also showing a moderate decrease, demonstrating the clear anti-inflammatory effect conferred by the incorporation of ZTCG. Moreover, the MNs@Z/CP-treated group showed markedly higher Ki67 fluorescence signal in wound regions, indicating enhanced cellular proliferative activity (Figure 8P and Figure S22).



**Figure 8. Mechanistic analysis of MNs@Z/CP-mediated promotion of diabetic wound healing.** (A) Volcano plot of DEGs between the MNs@Z/CP and blank groups. (B) Venn diagram of DEGs between the MNs@Z/CP and blank groups. (C) Clustering heatmap of DEGs. (D) GO enrichment analysis. (E, F) KEGG pathway analysis for up-regulated (E) and down-regulated (F) DEGs. (G–J) GSEA plot for the inflammatory response, IL-17 signaling pathway, cell killing and cell cycle pathway. (K–N) Fragments per kilobase million (FPKM) values of *IL-17a*, *IL-17ra*, *Mki67* and *Ndc80* (n = 3). (O) Immunohistochemical staining of IL-17 on day 12. (P) Immunofluorescence staining of Ki67 on day 12. Values are expressed as the mean ± SD. \*p < 0.05, \*\*p < 0.01.

Remarkably, the MNs@Z/CP-treated group showed higher expression of antioxidant enzyme-related genes, including *CAT* and *GPX7* (Figure S23), consistent with our *in vitro* findings. Collectively, these results demonstrate that MNs@Z/CP increases the production of antioxidant enzymes *in vivo*, scavenges ROS to alleviate oxidative stress, and remodels the wound microenvironment while blocking the IL-17-mediated inflammatory response. This promotes cell cycle progression and proliferation, exerting potent anti-inflammatory and pro-repair effects, and provides a crucial molecular basis for diabetic wound healing.

### **MNs@Z/CP promotes healing of MRSA-infected diabetic wounds through multi-dimensional mechanisms**

The hyperglycemic microenvironment in diabetic wounds facilitates secondary infections, and the clinical overuse of antibiotics exacerbates bacterial resistance [62, 63]. To evaluate the therapeutic potential of MNs@Z/CP against drug-resistant bacterial wound infections, we established a full-thickness MRSA-infected wound model on diabetic rats and applied the microneedles for treatment (Figure 9A).

Wound appearances on days 0, 4, 9, and 15 for each treatment group are shown in Figures 9B and 9C. After 15 days of therapy, the MNs@Z/CP group exhibited markedly reduced wound area and abscess size compared with the blank group (Figure 9E). Agar plate colony counting results (Figure 9D, F) revealed that MNs@Z/P treatment achieved an antibacterial rate of  $73.38 \pm 2.21\%$ , and the MNs@Z/CP group further increased this rate to  $94.88 \pm 1.04\%$  on day 9. This enhanced antibacterial effect may arise from the inherent antibacterial properties of the Ce-MOF component, which has been reported to possess potent bacteriostatic activity. Furthermore, no obvious pathological damage to the major organs of rats was observed after 15 days of treatment, demonstrating the system's superior *in vivo* biosafety and therapeutic potential (Figure S24).

H&E staining results (Figure 9G) showed that the blank and MNs/P groups displayed poor epidermal integrity, large wound areas, and substantial inflammatory cell infiltration. In contrast, the MNs@Z/P and MNs@Z/CP groups exhibited much smaller wound areas and significantly reduced inflammatory cell infiltration, with the MNs@Z/CP group showing the most pronounced benefit. Giemsa staining further indicated that the MNs@Z/P and MNs@Z/CP groups also had significantly fewer residual bacteria (blue arrows) than the blank and MNs/P groups [64], with the MNs@Z/CP group

achieving the most thorough bacterial clearance (Figure 9H and Figure S25). Masson's trichrome staining (Figure 9I) further showed that the MNs@Z/CP group exhibited the highest collagen deposition. Effective collagen deposition is essential during wound repair, and its increased content accelerates tissue regeneration. These results demonstrate that MNs@Z/CP can efficiently reduce inflammation, promote collagen production, and rebuild skin structure, thereby facilitating the healing of MRSA-infected diabetic wounds.


To further examine the anti-inflammatory effects of MNs@Z/CP and its regulatory capacity on macrophage polarization during the infected wound repair process, we performed immunohistochemical analyses on day 9. Immunohistochemical labeling revealed markedly higher expression levels of TNF- $\alpha$  and IL-6 in the blank and MNs/P groups than the other groups (Figure 9J, M, and N), suggesting a robust inflammatory response. In the MNs@Z/P group, TNF- $\alpha$  and IL-6 expression dropped, reflecting reduced inflammatory response due to the multi-enzyme activity, radical scavenging capacity of ZTCG nanozymes, and TA release. The MNs@Z/CP group further decreased the expression of these pro-inflammatory cytokines to the lowest level, owing to the synergistic antioxidant effect of the Ce-MOF nanoparticles, highlighting its superior anti-inflammatory performance.

Macrophage phenotypes were assessed using double immunofluorescence labeling for iNOS (red, M1) and CD206 (green, M2). The blank and MNs/P groups exhibited strong red fluorescence and weak green fluorescence, whereas the MNs@Z/CP group showed the opposite pattern (Figure 9K). Quantitative regional analysis (Figure 9O) indicated that both the MNs@Z/P ( $3.61 \pm 1.17$ ) and MNs@Z/CP ( $8.25 \pm 1.59$ ) groups exhibited higher M2/M1 macrophage ratios than the blank group ( $0.06 \pm 0.02$ ). The MNs@Z/CP group showed the greatest elevation, demonstrating its ability to effectively promote M2-type macrophage polarization. Additionally, CD31 immunofluorescence staining showed that the MNs@Z/P and MNs@Z/CP groups had considerably larger CD31-positive vascular areas than the blank group, indicating higher capillary density and active angiogenesis (Figure 9L, 9P). The  $\alpha$ -SMA-positive area also increased in these two groups, suggesting that ZTCG nanozymes support vascular maturation (Figure 9L). Notably, the MNs@Z/CP group exhibited a larger  $\alpha$ -SMA-positive area than the MNs@Z/P group (Figure 9Q). This may be attributed to the greater capacity of the MNs@Z/CP group to polarize macrophages toward the M2 phenotype, which in turn promotes the generation of more pro-angiogenic

cytokines [65].

In summary, MNs@Z/CP effectively eliminates deep bacterial infections and reduces the inflammatory cascade through its multiple antioxidant actions. By remodeling the local immune microenvironment, it promotes the transition of

macrophages to M2 phenotype, which subsequently stimulates the expression of pro-angiogenic factors, accelerates tissue regeneration and structural reconstruction, and ultimately enables rapid and excellent healing of MRSA-infected diabetic wounds.



**Figure 9. Therapeutic efficacy of MNs@Z/CP in MRSA-infected diabetic wounds.** (A) Experimental schematic of the wound model established. (B) Representative photographs of wound healing process in the blank, MNs/P, MNs@Z/P, and MNs@Z/CP groups. (C) Wound traces in each group on day 15. (D) Bacterial colony counts from wounds on day 4 and day 9 post-treatment. (E) Wound closure rate. (F) Quantitative evaluation of bacterial colonies from wounds. (G–I) H&E (G), Giemsa (H), and Masson (I) staining images (black arrows: wound area; blue arrows: bacteria). (J) Immunohistochemical staining images for TNF-α and IL-6 in wound tissues. (K) Immunofluorescence staining images for iNOS and CD206 in wound tissues. (L) Immunofluorescence staining images for α-SMA and CD31 in wound tissues. (M, N) Quantitative analysis of TNF-α (M) and IL-6 (N). (O) Ratio of M2 (CD206<sup>+</sup>) / M1 (iNOS<sup>+</sup>). (P, Q) Quantified areas positive for CD31 (P) and α-SMA (Q). Values are expressed as the mean ± SD. (n = 5). \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001.

## Conclusion

In conclusion, this work successfully established an intelligent bilayer microneedle system based on the integration of dual MOFs, establishing a novel paradigm of integrated therapy and monitoring for chronic wounds. This system effectively clears drug-resistant bacterial biofilms, remodels the oxidative stress microenvironment, modulates immune responses, and enables real-time monitoring of wound H<sub>2</sub>O<sub>2</sub> levels. Mechanistically, the system alleviates oxidative damage by triggering the Nrf2/HO-1 pathway and promotes macrophage reprogramming to M2 phenotype *in vitro*. It mitigates the inflammatory response by downregulating the IL-17 signaling pathway, synergistically promoting angiogenesis and collagen remodeling *in vivo*. These effects establish a comprehensive therapeutic framework encompassing anti-inflammatory, immunomodulatory, pro-angiogenic, and pro-proliferative mechanisms. This multi-layered spatial regulation strategy not only successfully addresses the challenges of intractable infection, oxidative stress imbalance, and inflammatory dysregulation in chronic wound healing, but also achieves on-demand precision therapy. This bilayer microneedle system effectively breaks the cycle of chronic inflammation by integrating monitoring functions with therapeutic interventions, laying the foundation for the next-generation smart wound management. Its potential applications extend to various refractory wounds, such as diabetic ulcers and drug-resistant bacterial infections.

## Supplementary Material

Supplementary figures and tables.

<https://www.thno.org/v16p6529s1.pdf>

## Acknowledgements

This work was supported by grants from Key Project of Jiangxi Provincial Natural Science Foundation (No. 20252BAC250080); National Key R&D Program of China (No. 2023YFC2507700); National Nature Science Foundation of China (No. 82360419; No. 31960207); Double-thousand Plan Program of Jiangxi Province (No. 8210298001); Clinical Cultivation Project of The First Affiliated Hospital of Nanchang University (No. YFYLCYJPY202202); Youth Program of Jiangxi Provincial Natural Science Foundation (No. 20232BAB216069, No. 20232BAB216033); The Jiangxi Province Key Research and Development Plan (No. 20232BBE50017). No artificial intelligence tools were used in the preparation of the manuscript, image generation, data collection, or data analysis.

## Authorship contribution statement

Fanrong Ai and Kai Cao: conceptualization. Zhenhai Zhou: methodology. Junlong Zhong: software. Yeke Chen: validation. Kang Chen, Zhiming Liu, Xinming Yang and Wen Tan: formal analysis. Wenlong Tang, Wanhui Zhou, and Degui Wu: investigation. Jiachao Xiong: resources. Shuai Fan and Kai Cao: data curation. Shuai Fan, Junlong Zhong and Yeke Chen: writing original draft. Shuai Fan, Fanrong Ai and Kai Cao: writing review and editing. Zhenhai Zhou: visualization. Kai Cao: project administration. All authors have read and agreed to the published version of the manuscript.

## Data availability statement

The data that support the findings of this study are available upon reasonable request.

## Competing Interests

The authors have declared that no competing interest exists.

## References

1. Armstrong DG, Boulton AJM, Bus SA. Diabetic Foot Ulcers and Their Recurrence. *N Engl J Med*. 2017; 376: 2367-75.
2. Zhang Y, Lazzarini PA, McPhail SM, van Netten JJ, Armstrong DG, Pacella RE. Global Disability Burdens of Diabetes-Related Lower-Extremity Complications in 1990 and 2016. *Diabetes Care*. 2020; 43: 964-74.
3. Theocharidis G, Yuk H, Roh H, Wang L, Mezghani I, Wu J, et al. A strain-programmed patch for the healing of diabetic wounds. *Nat Biomed Eng*. 2022; 6: 1118-33.
4. Shen Z, Du L, Fang X, Zhang Z, Li X, Xiao S, et al. Nanozyme Cryogel Accelerates Diabetic Wound Healing by Targeting Biofilms and Inflammations of the Wound Bed. *ACS Nano*. 2025; 19: 35081-101.
5. Huang J, Yang R, Jiao J, Li Z, Wang P, Liu Y, et al. A click chemistry-mediated all-peptide cell printing hydrogel platform for diabetic wound healing. *Nat Commun*. 2023; 14: 7856.
6. Yang F, Lv J, Gao X, Zhang K, Wang Y, Huang L, et al. Hydrogel-Powered Adversity Transformation: On-Demand Ultrasonic Switching Strategy for Accelerating Diabetic Wound Healing. *ACS Nano*. 2025; 19: 36813-25.
7. Zhou Q, Zhuang Y, Deng X, Jiang W, Wang X, Yuan C, et al. Hydrogel-Based ROS-Regulating Strategy: Reprogramming the Oxidative Stress Imbalance in Advanced Diabetic Wound Repair. *Adv Mater*. 2025; e12719.
8. Ge Y, Rong F, Lu Y, Wang Z, Liu J, Xu F, et al. Glucose Oxidase Driven Hydrogen Sulfide-Releasing Nanocascade for Diabetic Infection Treatment. *Nano Lett*. 2023; 23: 6610-8.
9. Zhang S, Zhao X, Zhang W, Wei X, Chen XL, Wang X. Zn-DHM nanozymes regulate metabolic and immune homeostasis for early diabetic wound therapy. *Bioact Mater*. 2025; 49: 63-84.
10. Demyanenko IA, Zakharova VV, Ilyinskaya OP, Vasilieva TV, Fedorov AV, Manskikh VN, et al. Mitochondria-Targeted Antioxidant SkQ1 Improves Dermal Wound Healing in Genetically Diabetic Mice. *Oxid Med Cell Longev*. 2017; 2017: 6408278.
11. Bock FJ, Tait SWG. Mitochondria as multifaceted regulators of cell death. *Nat Rev Mol Cell Biol*. 2020; 21: 85-100.
12. Chao D, Dong Q, Yu Z, Qi D, Li M, Xu L, et al. Specific Nanodrug for Diabetic Chronic Wounds Based on Antioxidase-Mimicking MOF-818 Nanozymes. *J Am Chem Soc*. 2022; 144: 23438-47.
13. Gong J, Ye C, Ran J, Xiong X, Fang X, Zhou X, et al. Polydopamine-Mediated Immunomodulatory Patch for Diabetic Periodontal Tissue Regeneration Assisted by Metformin-ZIF System. *ACS Nano*. 2023; 17: 16573-86.
14. Xiang J, Li Z, Tseng s, Li T, Wang L, Li Z, et al. Multifunctional MOF microneedle patch with adsorbed exosomes for enhanced diabetic wound healing. *Mater Today Bio*. 2025; 33: 102076.

15. Li Z, He M, Wang Y, Yang J, He Y, Chen X, et al. Advances in Biocompatible Metal-Organic Frameworks for Biomedical Applications. *Adv Mater.* 2025; 37: 2503946.
16. Astaneh ME, Hashemzadeh A, Fereydouni N. ZIF-8-based nanomaterials for diabetic wound healing: mechanisms, applications, and future perspectives. *J Mater Chem B.* 2025.
17. Liu X, Sun X, Peng Y, Wang Y, Xu D, Chen W, et al. Intrinsic Properties Enabled Metal Organic Framework Micromotors for Highly Efficient Self-Propulsion and Enhanced Antibacterial Therapy. *ACS Nano.* 2022; 16: 14666-78.
18. Zhu C, Fan Z, Cheng Z, Yin J, Qin L, Zhao X. Nature-derived microneedles with metal-polyphenolic networks encapsulation for chronic soft tissue defects repair: Responding and remodeling the regenerative microenvironment. *Mater Today Bio.* 2025; 31: 101539.
19. Yan Y, Ni M, Wang F, Yu Y, Gong X, Huang Y, et al. Metal-Organic Framework-Based Biosensor for Detecting Hydrogen Peroxide in Plants through Color-to-Thermal Signal Conversion. *ACS Nano.* 2022; 16: 15175-87.
20. Wang X, Fu J, Jiang C, Liao X, Chen Y, Jia T, et al. Specific and Long-Term Luminescent Monitoring of Hydrogen Peroxide in Tumor Metastasis. *Adv Mater.* 2023; 35: e2210948.
21. Liu Y, Luo X, Chen L, Qiao Z, Si C, Liu X. Dual-Layer Modular Microneedle-Based Biosensor for Advanced Precision Management of Infected Chronic Wounds. *Adv Funct Mater.* 2025; 15: e17521.
22. Lin X, Jia Q, Lin X, Shi J, Gong W, Shen K, et al. Galvanic Cell Bipolar Microneedle Patches for Reversing Photoaging Wrinkles. *Adv Mater.* 2025; 37: e2500552.
23. Huang J, Huang J, Zhang X, Xie Q, Zheng Y, Shu C, et al. A bioactive multifunctional dressing with simultaneous visible monitoring of pH values and H<sub>2</sub>O<sub>2</sub> concentrations for promoting diabetic wound healing. *Mater Horiz.* 2025; 12: 267-83.
24. Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. *Antioxid Redox Signal.* 2014; 20: 1126-67.
25. Chen Z, Song S, Zeng H, Ge Z, Liu B, Fan Z. 3D printing MOF nanozyme hydrogel with dual enzymatic activities and visualized glucose monitoring for diabetic wound healing. *Chem Eng J.* 2023; 471: 144649.
26. Zeng L, Ding S, Cao Y, Li C, Zhao B, Ma Z, et al. A MOF-Based Potent Ferroptosis Inducer for Enhanced Radiotherapy of Triple Negative Breast Cancer. *ACS Nano.* 2023; 17: 13195-210.
27. Luan X, Pan Y, Zhou D, He B, Liu X, Gao Y, et al. Cerium metal organic framework mediated molecular threading for point-of-care colorimetric assays. *Biosens Bioelectron.* 2020; 165: 112406.
28. Zhang H, Zhang J, Li Q, Song A, Tian H, Wang J, et al. Site-specific MOF-based immunotherapeutic nanoplatfoms via synergistic tumor cells-targeted treatment and dendritic cells-targeted immunomodulation. *Biomaterials.* 2020; 245: 119983.
29. Espina A, Cañamares MV, Jurašeková Z, Sanchez-Cortes S. Analysis of Iron Complexes of Tannic Acid and Other Related Polyphenols as Revealed by Spectroscopic Techniques: Implications in the Identification and Characterization of Iron Gall Inks in Historical Manuscripts. *ACS Omega.* 2022; 7: 27937-49.
30. Chen Y, Bai Y, Meng L, Zhang W, Xia J, Xu Z, et al. Engineering nanocomposite metal-phenolic network membranes with hollow MOFs via in-situ etching for High-efficiency organic solvent nanofiltration. *Chem Eng J.* 2022; 437: 135289.
31. Liu T, Ma M, Ali A, Liu Q, Bai R, Zhang K, et al. Self-assembled copper tannic acid nanoparticles: A powerful nano-bactericide by valence shift of copper. *Nano Today.* 2024; 54: 102071.
32. Zhang X, Zhong L, Liu S, Zhang L, Li C, Wang Q, et al. Coordination Polyphenol and Hydrogenation Coarmed Ce-Mo Bimetal Nanozymes for Robust Anticancer Therapy. *Adv Funct Mater.* 2025; 25: e18003.
33. Ma R, Deng Q, Lin Y, Gu S, Su Q, Wang Y, et al. Metal-Phenolic Networks-Based Nanozyme Reprograms Tumor Metabolism and Immunosuppressive Microenvironment to Enhance Ferroptosis and Potentiate Cancer Immunotherapy. *ACS Nano.* 2026; 20: 6983-7000.
34. He S, Li Z, Wang L, Yao N, Wen H, Yuan H, et al. A nanoenzyme-modified hydrogel targets macrophage reprogramming-angiogenesis crosstalk to boost diabetic wound repair. *Bioact Mater.* 2024; 35: 17-30.
35. Bao X, Zhao J, Sun J, Hu M, Yang X. Polydopamine Nanoparticles as Efficient Scavengers for Reactive Oxygen Species in Periodontal Disease. *ACS Nano.* 2018; 12: 8882-92.
36. Sies H, Belousov VV, Chandel NS, Davies MJ, Jones DP, Mann GE, et al. Defining roles of specific reactive oxygen species (ROS) in cell biology and physiology. *Nat Rev Mol Cell Biol.* 2022; 23: 499-515.
37. Tao N, Li H, Deng L, Zhao S, Ouyang J, Wen M, et al. A Cascade Nanozyme with Amplified Sonodynamic Therapeutic Effects through Comodulation of Hypoxia and Immunosuppression against Cancer. *ACS Nano.* 2022; 16: 485-501.
38. Dong S, Dong Y, Liu B, Liu J, Liu S, Zhao Z, et al. Guiding Transition Metal-Doped Hollow Cerium Tandem Nanozymes with Elaborately Regulated Multi-Enzymatic Activities for Intensive Chemodynamic Therapy. *Adv Mater.* 2022; 34: e2107054.
39. Zhang S, Ge G, Qin Y, Li W, Dong J, Mei J, et al. Recent advances in responsive hydrogels for diabetic wound healing. *Mater Today Bio.* 2023; 18: 100508.
40. Weng Z, Zeng F, Wang M, Guo S, Tang Z, Itagaki K, et al. Antimicrobial activities of lavandulylated flavonoids in *Sophora flavescens* against methicillin-resistant *Staphylococcus aureus* via membrane disruption. *J Adv Res.* 2024; 57: 197-212.
41. Tan L, Li J, Liu X, Cui Z, Yang X, Zhu S, et al. Rapid Biofilm Eradication on Bone Implants Using Red Phosphorus and Near-Infrared Light. *Adv Mater.* 2018; 30: e1801808.
42. Shi S, Bai M, Kong L, Li J, Ding X, Yang J, et al. Spatiotemporal oxygen modulation reprograms hypoxia-induced antibiotic resistance. *Chem Eng J.* 2025; 525: 170595.
43. Wang Z, Chen F, Wang Z, Wu M, Jiang M, Zheng Z, et al. Chiral Single-Atom Nanozymes-Enabled ROS Catalysis and Metal Transport Regulation Cooperatively Induce Ferroptosis to Treat Bacterial Infections. *Adv Mater.* 2026; 38: e18810.
44. Chen Z, Li H, Bian Y, Wang Z, Chen G, Zhang X, et al. Bioorthogonal catalytic patch. *Nat Nanotechnol.* 2021; 16: 933-41.
45. Wei M, Ran Z, Li Y, Song P, Mei J, Zhang H, et al. A Biofilm-Disrupting Microneedle Patch Leveraging DNA-Hydrolyzing Nanozyme and Photothermia for Enhanced Diabetic Ulcer Therapy. *Adv Healthcare Mater.* 2026; e05929.
46. Kang HJ, Kumar S, D'Elia A, Dash B, Nanda V, Hsia HC, et al. Self-assembled elastin-like polypeptide fusion protein coacervates as competitive inhibitors of advanced glycation end-products enhance diabetic wound healing. *J Control Release.* 2021; 333: 176-87.
47. Sun J, Jia W, Qi H, Huo J, Liao X, Xu Y, et al. An Antioxidative and Active Shrinkage Hydrogel Integratedly Promotes Re-Epithelization and Skin Constriction for Enhancing Wound Closure. *Adv Mater.* 2024; 36: e2312440.
48. Yang Y, Chen N, Fan J, Fan L, Cai Y, Xue L, et al. Spatiotemporal Immunomodulation of Macrophages via NLRP3/IL-1 $\beta$  Pathway by Core-Shell Microneedles to Promote Healing of Biofilm-Infected Diabetic Ulcers. *Small.* 2025; 21: e2505179.
49. Liao Y, Zhang Z, Hu W, Zhang S, Zhao Y, Ouyang L, et al. Glucose-regulating hydrogel for immune modulation and angiogenesis through metabolic reprogramming and LARP7-SIRT1 pathway in infected diabetic wounds. *Biomaterials.* 2025; 318: 123182.
50. Yuan X, Xiong J, Wu X, Ta N, Liu S, Li Z, et al. Ultrasmall Ce-based metal-organic frameworks nanozyme with hydrolytic activity for boosting antibiofilm therapy. *Chem Eng J.* 2024; 480: 148246.
51. Zhang L, Meng W, Chen X, Wu L, Chen M, Zhou Z, et al. Multifunctional Nanoplatfom for Mild Microwave-Enhanced Thermal, Antioxidative, and Chemotherapeutic Treatment of Rheumatoid Arthritis. *ACS Appl Mater Interfaces.* 2023; 15: 10341-55.
52. Qin M, Zhang X, Ding H, Chen Y, He W, Wei Y, et al. Engineered Probiotic Bio-Heterojunction with Robust Antibiofilm Modality via "Eating" Extracellular Polymeric Substances for Wound Regeneration. *Adv Mater.* 2024; 36: e2402530.
53. Mandakhbayar N, Ji Y, El-Fiqi A, Patel KD, Yoon DS, Dashnyam K, et al. Double hits with bioactive nanozyme based on cobalt-doped nanoglass for acute and diabetic wound therapies through anti-inflammatory and pro-angiogenic functions. *Bioact Mater.* 2024; 31: 298-311.
54. Li X, Feng L, Wu H, Yang H, Wang P, Chen Y, et al. Multifunctional Janus hydrogel targeting mitochondrial regulation and inflammatory pathways promotes infected burn wound repair. *Chem Eng J.* 2025; 517: 164423.
55. Pankoke K, Nielsen SS, Jørgensen BM, Jensen HE, Barington K. Immunohistochemical study of CD31 and  $\alpha$ -SMA expression for age estimation of porcine skin wounds. *J Comp Pathol.* 2023; 206: 22-31.
56. Qi X, Cai E, Xiang Y, Zhang C, Ge X, Wang J, et al. An Immunomodulatory Hydrogel by Hyperthermia-Assisted Self-Cascade Glucose Depletion and ROS Scavenging for Diabetic Foot Ulcer Wound Therapeutics. *Adv Mater.* 2023; 35: e2306632.
57. Chen X, Peng Y, Xue H, Liu G, Wang N, Shao Z. MiR-21 regulating PVT1/PTEN/IL-17 axis towards the treatment of infectious diabetic wound healing by modified GO-derived biomaterial in mouse models. *J Nanobiotechnology.* 2022; 20: 309.
58. Mu X, Gu R, Tang M, Wu X, He W, Nie X. IL-17 in wound repair: bridging acute and chronic responses. *Cell Commun Signal.* 2024; 22: 288.

59. Zhou X, Ma P, Liu Y, Wang Z, Chen S, Cheng Z, et al. Sprayable hydrogel sponge for neurovascular microenvironment reconstruction and inflammation modulation in diabetic wound healing. *Bioact Mater.* 2025; 54: 352-70.
60. Xue Y, Yang F, He Y, Wang F, Xia D, Liu Y. Multifunctional Hydrogel with Photothermal ROS Scavenging and Antibacterial Activity Accelerates Diabetic Wound Healing. *Adv Healthc Mater.* 2025; 14: e2402236.
61. Pereira Beserra F, Sérgio Gushiken LF, Vieira AJ, Augusto Bérnago D, Luísa Bérnago P, Oliveira de Souza M, et al. From Inflammation to Cutaneous Repair: Topical Application of Lupeol Improves Skin Wound Healing in Rats by Modulating the Cytokine Levels, NF- $\kappa$ B, Ki-67, Growth Factor Expression, and Distribution of Collagen Fibers. *Int J Mol Sci.* 2020; 21.
62. Fang G, Dong Q, Shen X, Ye R, Chang Y, Pu K, et al. Modulation of Bacterial Iron Homeostasis to Enhance Cuproptosis-like Death for the Treatment of Infected Diabetic Wound. *ACS Nano.* 2025; 19: 15578-95.
63. Wang N, Mu W, Kolesnik IA, Potkin VI, Li L, Feng X, et al. A Self-Oxygenating Nanozyme Cascade System for Drug-Resistant Bacterial Infected Diabetic Wound Healing. *ACS Appl Mater Interfaces.* 2025.
64. Geng Z, Dong R, Li X, Xu X, Chen L, Han X, et al. Study on the Antibacterial Activity and Bone Inductivity of Nanosilver/PLGA-Coated Ti-CU Implants. *Int J Nanomedicine.* 2024; 19: 6427-47.
65. Liao Z, Liang L, Fang H, Cui Y, Liang C, Huang G, et al. Exogenous M2 Macrophage-Loaded Scaffolds Promote Early Periodontal Regeneration by Improving Osteogenic Differentiation, Cell Homing, and Angiogenesis. *Adv Healthc Mater.* 2025; 14: 2501428.